Author Dr. Abraham Rami Tzafriri is the Director of Research and Innovation at CBSET Inc., in Lexington,
MA, United States, an AAALAC-accredited, GLP-compliant animal contract research institution dedicated to supporting and accelerating the advancement of novel therapeutics, devices, and procedures through ongoing collaboration between R&D researchers, the institute’s scientific staff, and key opinion-leader physicians and scientists.
Dr. Tzafriri also directs CBSET's internship and fellowship programs dedicated to training the next generation of interdisciplinary transnational researchers. He received his Ph.D. from the Hebrew University of Jerusalem for his research on biodegradable controlled-release devices and their use in the treatment of gingivitis and mammary tumors.
Dr. Tzafriri later held a post-doctoral research position at Elazer Edelman’s Harvard–MIT Biomedical Engineering Center, with a focus on the development of ex vivo and computational models to examine how blood flow and receptor–ligand interactions affect drug distribution in arteries and in the myocardium. He has published works on enzyme kinetics, drug transport, arteries, stents, growth factors, vascular medicine, renal denervation, and drug-coated balloons. His scientific output includes 46 publications, corresponding to 1708 citations (h-index 21) (Scopus, 13 November 2023).
Author Dr. Abraham Rami Tzafriri is the Director of Research and Innovation at CBSET Inc., in Lexington,
MA, United States, an AAALAC-accredited, GLP-compliant animal contract research institution dedicated to supporting and accelerating the advancement of novel therapeutics, devices, and procedures through ongoing collaboration between R&D researchers, the institute’s scientific staff, and key opinion-leader physicians and scientists.
Dr. Tzafriri also directs CBSET's internship and fellowship programs dedicated to training the next generation of interdisciplinary transnational researchers. He received his Ph.D. from the Hebrew University of Jerusalem for his research on biodegradable controlled-release devices and their use in the treatment of gingivitis and mammary tumors.
Dr. Tzafriri later held a post-doctoral research position at Elazer Edelman’s Harvard–MIT Biomedical Engineering Center, with a focus on the development of ex vivo and computational models to examine how blood flow and receptor–ligand interactions affect drug distribution in arteries and in the myocardium. He has published works on enzyme kinetics, drug transport, arteries, stents, growth factors, vascular medicine, renal denervation, and drug-coated balloons. His scientific output includes 46 publications, corresponding to 1708 citations (h-index 21) (Scopus, 13 November 2023).